Committed to taking ophthalmology to greater heights
About Us
Our company name, Centricity Vision, Inc., reflects our company’s expertise, expanded product offerings in cataract surgery, and continued commitment to customers and patients.
As a global ophthalmic technology company, we take pride in delivering innovative solutions that help surgeons across the world achieve surgical and clinical excellence.
Currently, we’re focusing on our unprecedented ZEPTO IOL Positioning System™. Designed to enhance the precision and efficiency of cataract surgery, the ZEPTO IOL Positioning System™ is the first and only device that creates an instantaneous capsulotomy for precise, 360-degree IOL overlap and improved outcomes. ZEPTO is ideal for premium IOLs and complex cases that require enhanced precision. ZEPTO also provides significant cost and time savings with easy workflow integration and increased efficiency per case.
Moving forward, we’ll leverage this microsurgical technology to create a suite of products for refractive cataract surgery management. Our relentless commitment to developing solutions of the highest quality and technological sophistication is uncompromising—as is our dedication to assisting physicians in delivering the best care to patients.
Leadership Team
News and Events
Upcoming News
Upcoming Events
REFERENCE 1: Thompson V. Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis. J Cataract Refract Surg. 2018;44(5):528-533.
Rob Thornhill
President & CEO
Rob is a start-up and large company medical device executive with equity fund-raising, business development, clinical study, and successful exit transactional experience. He has deep commercial operational experience with teams of up to 200 employees. Prior to joining Centricity Vision, Inc., Rob served as the founding CEO of Tear Film Innovations, Inc.,–manufacturer of the iLux treatment device for dry eye disease, which he led from seed stage through a Series B financing and then successfully sold to Alcon in 2018.
Louis Bunn
Chief Financial Officer
Louis has more than 26 years of experience as a senior financial executive with early-stage medical device companies. He was instrumental in raising in excess of $200 million in venture equity and debt as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value. Prior to joining Centricity Vision, Louis was CFO of ReVision Optics, Inc., a corneal inlay company. Prior experience included serving as CFO and participating in the sale of 3F Therapeutics, Inc., a tissue heart-valve company, acquired by ATS Medical, Inc., EndiCOR Medical, Inc., a coronary catheter company, acquired by Ev3, Inc., and SenDx Medical, Inc., a critical care diagnostic company, acquired by Radiometer. Prior to joining SenDx, Louis served as a Senior Audit Manager with Ernst & Young.
Todd M. Pinkney
Chief Commercial Officer
Todd is a proven medical device and biotechnology commercial leader with an achievement record of more than 27 years. He demonstrated success in driving multimillion-dollar revenue growth while providing strategic marketing and sales leadership in highly competitive markets. Todd has commercial expertise in start-up, turnaround, and mature companies with significant business development and capital fundraising exposure. Prior to joining Centricity Vision, Todd led all commercial launch efforts for the XEN® Surgical Treatment System at Allergan. Todd graduated from Temple University with a Master’s Degree in International Business and holds a B.S. in Marketing from of Pittsburgh.
Dr. Leonard R. Borrmann
Head of Research and Development
Dr. Leonard R. Borrmann brings a wealth of product development, clinical, and regulatory expertise to Centricity Vision leading R&D initiatives for the company. Dr. Borrmann joined Johnson & Johnson in 2017 with the acquisition of Abbott Medical Optics where he was the Divisional Vice President of Research and Development and retired from J&J as Global Head of External Innovation in 2020. Prior to joining Abbott, Dr. Borrmann held positions of increasing responsibility in R&D, including Executive Vice President R&D with Advanced Medical Optics (acquired by Abbott in 2009). During his 13 years with AMO, Dr. Borrmann led the development and launch of more than 30 new products for AMO’s cataract, refractive and corneal businesses. Prior to joining AMO, Dr. Borrmann was CEO and director for a series of venture-backed biotech companies and had a 15-year career at Allergan Pharmaceuticals Inc., where he held positions of increasing responsibility in Clinical Research, Marketing and Business Development, including Vice President of Business Development.
Dr. Borrmann earned his bachelor’s degree in Psychobiology and Doctor of Pharmacy degree from University of Southern California.
Nealen Hartman
Vice President, RA and Quality Assurance
Nealen has more than 20 years of experience with start-ups to large medical device companies supporting regulatory affairs, quality assurance, and quality engineering. He gained FDA clearance and international registration of various types of devices ranging from single-use disposables to electro mechanical devices. Nealen established and maintained quality management systems that have been successfully audited and inspected by the FDA, notified bodies, and international entities. He was also involved with a handful of acquisitions, with the latest being the acquisition of Tear Film Innovation, Inc. by Alcon.